Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: LY 170053; LY-170052; Midax; Olanzapine controlled-release; Olanzapine LAI; Olanzapine long-acting; Olanzapine pamoate; Zypadhera; Zyprexa; Zyprexa Relprevv; Zyprexa Velotab; Zyprexa Zydis

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antipsychotics; Benzodiazepines; Oxazepines; Small molecules; Thiazepines
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aggression; Bipolar depression; Bipolar disorders; Manic episodes; Schizophrenia
  • Phase III Major depressive disorder
  • No development reported Anorexia nervosa; Huntington's disease; Personality disorders

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Huntington's-disease in Russia (PO)
  • 15 Mar 2016 Biomarkers information updated
  • 05 Feb 2016 Eli Lilly terminates a phase III trial in Major depressive disorder (Treatment-resistant, Combination therapy) in China due to lack of efficacy in interim results (NCT01687478)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top